Pfizer Has Tafamidis Data In Hand, But Market Development Still A Challenge

Unveiling its Phase III data showing both an all-cause mortality and cardiovascular hospitalization benefit, Pfizer thinks it can bring dramatic improvement in therapy for transthyretin cardiomyopathy.